Vitiligo (B7981040)
20210622141911

A Phase 3 randomized, double-blind, 52-week (placebo-controlled for 36 weeks with a 16-week extension period), multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib (PF-06651600) in adult and adolescent participants with non-segmental vitiligo (both participants with active and no more than 50% of participants with stable vitiligo).

Biogen – 230LE301/302 – Lupus
20201207134500

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations